Cuba publishes results of Soberana Pediatria vaccine clinical trial

HAVANA, Cuba, Mar 7 (ACN) The main results of the Soberana Pediatria (" Soberana Pediatrics ") clinical trial, published on Sunday on the MedRxiv. repository, were released by Dagmar Garcia Rivera, research director of the Finlay Institute of Vaccines.

On her Facebook account, the scientist pointed out that, from day zero, Soberana was designed for children, which is why nowadays the results of the studies are excellent, in the three to 18 years old pediatric population, and particularly, in three to 11 years old children.

With two doses of Soberana 02, 95 % of the children had seroconversion (four-fold increase in antibodies), and 100 % after the third dose, with Soberana Plus, Garcia Rivera indicated.

As for the immune response, she explained that it is higher than that induced by natural infection, when two doses of Soberana 02 are applied, and all the immunological variables are significantly increased with a third dose of Soberana Plus.

As further evidence, no serious or severe events were reported: only local pain had a frequency greater than 10 %.

According to the researcher, there are neutralizing antibodies against the alpha, beta and delta variants of the SARS-CoV-2 virus, and the results of omicron are still pending.

In addition, there is a specific T-cell response against the virus, and statistically, there is no inferiority of the neutralizing antibody response to young adults.

The immunogenicity data predict a clinical efficacy of more than 90 %, she noted.

Currently, 1.8 million Cuban children and more than 1 million Nicaraguan infants are vaccinated with Soberana.